Diabetes type 2 prevalence is rising among young residents in Malmö, Sweden

Abstract

Aim

Type 2 diabetes is becoming more prevalent in many parts of the world. Malmö’s population has increased in recent years mainly because of migration from other parts of Sweden and the world in addition to increased birth rates. We aimed to explore diabetes prevalence in Malmö in 2011–2018 as well as the achieved treatment targets for selected diabetes-related outcomes.

Method

The current study is a part of the Cities Changing Diabetes Malmö project. Prevalence data were retrieved from the region’s primary care and hospital diagnosis register, and data on treatment targets were collected from the National Diabetes Register. The inclusion criteria were either being a resident of Malmö or using a primary healthcare centre located in Malmö.

Results

The prevalence of type 2 diabetes in 2018 doubled from 2011 in the entire Malmö population. During the same period, the prevalence of type 1 diabetes remained stable at 0.49 %. In 2011, the type 2 diabetes prevalence was 2.46 % (2.76 % for males and 2.28 % for females), and in 2018, it was 4.26 % (4.84 % for males and 3.82 % for females). The increase was 139 % for residents aged 0–29 years, 119.6 % for residents aged 30–39 years, 96.2 % for residents aged 40–49 years, 102 % for residents aged 50–59 years, 98.2 % for residents aged 60–69 years, and 115.5 % for those aged 70–79 years. Finally, the increase was 60.9 % for those aged 80–84 years and 90.7 % for residents 90 years of age and older. The National Diabetes Register reported that during 2019, 58 % of all patients with diabetes using primary care in Malmö reached HbA_1c <52 mmol/mol, 20 % had albuminuria, 36 % had retinopathy, and 21 % had not had their feet inspected by a healthcare professional during the last year. The median HbA_1c was 52.6 mmol/mol, and 17 % were registered as active smokers.

Conclusion

Diabetes prevalence in Malmö has increased markedly in recent years, exacerbated by a rise in type 2 diabetes mainly in the younger population. Targets regarding p-glucose lowering treatments were not met by 42 %. One patient out of three had microvascular complications in the eye, one out of five had impaired kidney function, one out of five had not had their feet inspected, and one out of five was an active smoker. Active diabetes treatments need to be improved to reduce the number of younger patients developing microvascular complications. Preventive activities need to target younger populations to counteract even more residents developing type 2 diabetes.